Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys
- PMID: 2392504
- DOI: 10.1007/BF02245739
Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys
Abstract
Intermittent treatment with L-dopa over a 2-year period induced abnormal involuntary movements in MPTP-treated squirrel monkeys. Dyskinesias included a choreic and dystonic component. Dose-response curves for chorea and dystonia revealed that the same dose of L-dopa (30 mg/kg) induced the highest score for both dyskinesias: however, the severity was much greater for chorea. Choreic movements were always most prevalent at the time of peak effect, whereas dystonia was apparent at the time of peak effect and at "end-of-dose", and was occasionally observed spontaneously. Our findings indicate that squirrel monkeys treated with MPTP develop L-dopa-induced dyskinesias which closely resemble those observed in Parkinson's disease. This species provides a valuable animal model to develop improved therapeutic agents.
Similar articles
-
Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets.Psychopharmacology (Berl). 1999 Feb;142(1):51-60. doi: 10.1007/s002130050861. Psychopharmacology (Berl). 1999. PMID: 10102782
-
NB-355: a novel prodrug for L-DOPA with reduced risk for peak-dose dyskinesias in MPTP-treated squirrel monkeys.Clin Neuropharmacol. 1989 Oct;12(5):393-403. Clin Neuropharmacol. 1989. PMID: 2611764
-
Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).Mov Disord. 1995 Nov;10(6):731-40. doi: 10.1002/mds.870100606. Mov Disord. 1995. PMID: 8749992
-
The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications.Neurology. 2003 Sep 23;61(6 Suppl 3):S4-11. doi: 10.1212/wnl.61.6_suppl_3.s4. Neurology. 2003. PMID: 14504374 Review.
-
Animal models of l-dopa-induced dyskinesia in Parkinson's disease.Mov Disord. 2018 Jul;33(6):889-899. doi: 10.1002/mds.27337. Epub 2018 Feb 28. Mov Disord. 2018. PMID: 29488257 Review.
Cited by
-
Pathophysiology of dyskinesia and behavioral disorders in non-human primates: the role of serotonergic fibers.J Neural Transm (Vienna). 2018 Aug;125(8):1145-1156. doi: 10.1007/s00702-018-1871-7. Epub 2018 Mar 3. J Neural Transm (Vienna). 2018. PMID: 29502255 Review.
-
Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study.J Neural Transm (Vienna). 1996;103(6):699-715. doi: 10.1007/BF01271230. J Neural Transm (Vienna). 1996. PMID: 8836932 Clinical Trial.
-
L-dopa dose and the duration and severity of dyskinesia in primed MPTP-treated primates.J Neural Transm (Vienna). 2007 Sep;114(9):1147-53. doi: 10.1007/s00702-007-0727-3. Epub 2007 Apr 20. J Neural Transm (Vienna). 2007. PMID: 17446998
-
Preclinical Evidence for a Role of the Nicotinic Cholinergic System in Parkinson's Disease.Neuropsychol Rev. 2015 Dec;25(4):371-83. doi: 10.1007/s11065-015-9303-z. Epub 2015 Nov 9. Neuropsychol Rev. 2015. PMID: 26553323 Review.
-
Transient dystonia correlates with parkinsonism after 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine in nonhuman primates.Dystonia. 2023;2:11019. doi: 10.3389/dyst.2023.11019. Epub 2023 Feb 1. Dystonia. 2023. PMID: 37711667 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources